Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial

American Journal of Hematology

Volumn 93, Issue 5, 2018, Pages 655-663

  Candoni, Anna ^a   Papayannidis, Cristina ^b   Martinelli, Giovanni ^b   Simeone, Erica ^a   Gottardi, Michele ^c   Iacobucci, Ilaria ^b   Gherlinzoni, Filippo ^c   Visani, Giuseppe ^d   Baccarani, Michele ^b   Fanin, Renato ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Hospital of Treviso   (Italy)

^d SAN SALVATORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CYTARABINE; DIPHENHYDRAMINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; IDARUBICIN; METHYLPREDNISOLONE; PARACETAMOL; WT1 PROTEIN; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; CD33 PROTEIN, HUMAN; GEMTUZUMAB; MONOCLONAL ANTIBODY; VIDARABINE;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; BLOOD TOXICITY; CLINICAL OUTCOME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; ENCEPHALITIS; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INFUSION RELATED REACTION; LONG TERM CARE; LOW DRUG DOSE; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MORTALITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLATELET COUNT; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PYREXIA IDIOPATHICA; REMISSION; SINGLE DRUG DOSE; TOXIC HEPATITIS; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; INDUCTION CHEMOTHERAPY; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; HUMANS; IDARUBICIN; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; SIALIC ACID BINDING IG-LIKE LECTIN 3; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 85042797200     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.25057     Document Type: Article

References (52)

1. Döhner H, Estey E, Grimwade D. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2017;129(4):424–447.
2. Estey E. Why is progress in acute myeloid leukemia so slow?. Semin Hematol. 2015;52(3):243–248.
3. Freireich EJ, Wiernik PH, Steensma DP. The leukemias: a half-century of discovery. J Clin Oncol. 2014;32(31):3463–3469.
4. Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014;28(4):143–153.
5. Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31(9):1855–1868. https://doi.org/10.1038/leu.2017.187. [Epub ahead of print].
6. Pagano L, Fianchi L, Caira M, Rutella S, Leone G. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene. 2007;26(25):3679–3690.
7. Guolo F, Minetto P, Clavio M, et al. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: a critical review of a 10-year, single-center experience in younger, non M3 AML patients. Am J Hematol. 2016;91(8):755–762.
8. Stasi R, Evangelista ML, Buccisano F, Venditti A, Amadori S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev. 2008;34(1):49–60.
9. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–3354.
10. Li X, Xu SN, Qin DB, Tan Y, Gong Q, Chen JP. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials. Ann Oncol. 2014;25(2):455–461.
11. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase III study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–4860.
12. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–996.
13. Delaunay J, Recher C, Pigneux A. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR Study. Presented at ASH 2011. Blood. 2011;118:37–38.
14. Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a winner comparison. Leukemia. 2013;27(1):75–81.
15. Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–1516.
16. Rowe JM, Löwenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood. 2013;121(24):4838–4841.
17. Ravandi F, Estey EH, Appelbaum FR, et al. Gemtuzumab ozogamicin: time to resurrect?. J Clin Oncol. 2012;30(32):3921–3923.
18. Estey E. Treatment of AML: resurrection for gemtuzumab ozogamicin?. Lancet. 2012;379(9825):1468–1469.
19. Foran JM. Gemtuzumab: time to bring back on the market?. Clin Adv Hematol Oncol. 2012;10(5):326–327.
20. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474.
21. Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002;16(10):2115–2121.
22. Cilloni D, Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndromes. Acta Haematol. 2004;112(1–2):79–84.
23. Small D. FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program. 2006;2006(1):178–184.
24. Damiani D, Tiribelli M, Raspadori D, et al. The role of MDR-related proteins in the prognosis of adult acute myeloid leukemia (AML) with normal karyotype. Hematol Oncol. 2007;25(1):38–43.
25. Malagola M, Damiani D, Martinelli G, et al. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukemia patients. Br J Haematol. 2007;136(1):87–95.
26. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international Working Group for Diagnosis, Standardization of response Criteria, Treatment Outcomes, and reporting Standards for therapeutic Trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–4649.
27. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490–1496.
28. Giles F, Estey E, O'brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer. 2003;14:1436–1443.
29. Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16(9):1627–1636.
30. Loke J, Khan JN, Wilson JS, Craddock C, Wheatley K. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol. 2015;94(3):361–373.
31. Tsimberidou A-M, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol. 2006;132(4):398–409.
32. Pilorge S, Rigaudeau S, Rabian F, et al. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late firs relapse. Am J Hematol. 2014;89(4):399–402.
33. Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer. 2012;118(3):761–769.
34. Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AML0531. J Clin Oncol. 2014;32(27):3021–3032.
35. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003;102(13):4277–4283.
36. Candoni A, Martinelli G, Gherlinzoni F, et al. Low dose Gemtuzumab ozogamicin plus FLAI as induction therapy in CD33-positive AML. Definitive results and long-term outcome of a phase II multicenter prospective clinical trial (NCT.00909168). Haematologica. 2014;99:33.
37. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369–377.
38. Castaigne S. Why is it so difficult to use gemtuzumab ozogamicin? Blood. 2013;121:4813–4814.
39. Michelutti A, Michieli M, Damiani D, et al. Effect of fludarabine and arabinosyl cytosine on multidrug resistant cells. Haematologica. 1997;82(2):143–147.
40. Matsui H, Takeshita A, Naito K, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia. 2002;16(5):813–819.
41. Naito K, Takeshita A, Shigeno K. Calicheamicin-conjugated humanized anti- CD33 monoclonal antibody (gemtuzumab ozogamicin, CMA-676) shows cytotoxic effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2003;98:10
42. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood. 2003;102(4):1466–1473.
43. Linenberger ML, Hong T, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 2001;98(4):988–994.
44. Walter RB, Gooley TA, van der Velden VH, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007;109(10):4168–4170.
45. Jedema I, Barge RM, van der Velden VH, et al. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia. 2004;18(2):316–325.
46. van der Velden VH, Boeckx N, Jedema I, et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia. 2004;18(5):983–988.
47. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol. 2001;41(11):1206–1214.
48. Minetto P, Guolo F, Clavio M, et al. Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. Br J Haematol. 2018. https://doi.org/10.1111/bjh.15106. [Epub ahead of print]
49. Frairia C, Aydin S, Audisio E, et al. Post-remissional and pre.transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: a retrospective cohort study. Leuk Res. 2017;61:10–17.
50. McKoy JM, Angelotta C, Bennett CL, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31(5):599–604.
51. Candoni A, Fanin R, Baccarani M. Gemtuzumab ozogamicin combined with induction chemotherapy in young adults with acute myeloid leukemia: review and perspectives. Ann Hematol Oncol. 2015;2(7):1–6.
52. Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21(1):66–71.